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End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms underlying disease
progression are not fully elucidated. This work addressed nephrotoxicity induced by the immunosuppressive agents’ cyclosporine
A (CsA) and sirolimus (SRL). Nephrotoxicity is the major limiting factor in long term use of CsA. SRL causes less nephrotoxicity
than CsA. Therefore investigations into the diﬀerential eﬀects of these agents may identify potential mechanisms of nephrotoxicity
and means to prevent ESRD induced by therapeutic drugs. Using ELISA, Western blotting, quantitative PCR and a reporter gene
assay we detailed the diﬀerential eﬀects of CsA and SRL in human renal mesangial cells. CsA treatment increased proﬁbrotic TGF-
β1 secretion in human mesangial cells whereas SRL did not, indicating a role for TGF-β in CsA toxicity. However we observed
a synergistic nephrotoxic eﬀect when CsA and SRL were co-administered. These synergistic alterations may have been due to
an increase in CTGF which was not evident when the immunosuppressive drugs were used alone. The CsA/SRL combination
therapy signiﬁcantly enhanced Smad signalling and altered the extracellular matrix regulator matrix metalloproteinase 9 (MMP-
9). Inhibition of the ERK 1/2 pathway, attenuated these CsA/SRL induced alterations indicating a potentially signiﬁcant role for
this pathway.
1.Introduction
Cyclosporine A has improved allograft survival and the
quality of life for solid-organ transplant recipients [1].
Its eﬀectiveness in transplantation by suppression of the
immune system has led to its use in treating autoimmune
diseases [2]. CsA inhibits the immune system by binding
to cyclophilin, this complex then inhibits calcineurin, which
in turn inhibits the translocation of the nuclear factor of
activated T cells (NFAT) and subsequent gene transcription
[3]. Calcineurin inhibitors (CNI) can cause nephrotoxic-
ity involving acute renal vasoconstriction progressing on
to glomerulosclerosis, tubulointerstitial ﬁbrosis, and renal
failure.
Due to CNI-induced nephrotoxicity, the use of the
immunosuppressive agent sirolimus (SRL) in transplanta-
tions is becoming more widespread. SRL has a diﬀerent
mechanism of immunosuppression compared to CNIs, and
a lesser degree of nephrotoxicity is observed with SRL
compared to that observed with the calcineurin inhibitors
[4, 5]. When administered with a CNI, SRL may prevent
the observed nephrotoxic eﬀects. In both animal and human
studies, SRL has been suggested to have a protective role
when administered in conjunction with CsA [6, 7]. The
Rapamune US Study Group conducted a large multicentre
clinical trial in which the eﬃcacy of SRL compared to
azathioprine for reducing acute renal allograft rejection
was investigated. The use of SRL reduced occurrence and
the severity of biopsy-proven acute rejection episodes [8].
However, there have also been studies indicating enhanced
nephrotoxicity when SRL and CsA are used in combination
[9, 10]. In another study, the authors showed that a
combination of SRL and CsA signiﬁcantly potentiated the
nephrotoxic actions of CsA by augmenting transforming
growth factor β (TGF-β)[ 11].
TGF-β has been implicated as a major factor in the
development of chronic CNI toxicity. Increased TGF-β levels
have been observed in renal cells exposed to CsA, in2 Journal of Transplantation
animal models of CsA toxicity and in patients with CNI
nephropathy [12–15]; however, the nephrotoxicity caused by
CsA remains to be fully elucidated. In this study, the role
of the glomerulus in in vitro CsA toxicity was investigated.
Our hypothesis was to determine whether CsA or SRL had
direct detrimental eﬀects on the glomerulus and identify the
possible mechanisms involved, using glomerular mesangial
cells.
Human mesangial cells (HMCs) are key cells of the
glomerulus and have an important role in regulating
glomerular structure and function and have the potential
to contribute to glomerulosclerosis by secreting proﬁbrotic
mediators, which can alter extracellular matrix (ECM)
balance and disrupt renal function [16]. This may be an
important mechanism in renal disease progression and the
upstream signalling pathways involved in CsA-induced renal
dysfunction are not well characterised and warrants further
investigation. One intracellular pathway that may potentially
be involved in immunosuppressive-induced renal damage is
that of the mitogen-activated protein kinase (MAPK) family,
which has been implicated in TGF-β-induced cytotoxicity
[17]. The analysis of the diﬀerential activation of this
pathway may provide a novel insight into the mechanisms
of nephrotoxicity caused by CsA.
2. Methods
2.1. Cell Culture and Treatment. Human mesangial cells
(HMCs) were used during the course of this work [18].
The HMCs were grown in RPMI 1640 containing 5% FCS,
penicillin, streptomycin, and L-glutamine and maintained
at 37◦C in a humidiﬁed atmosphere containing 95% air,
5% CO2. CsA was obtained from Sigma-Aldrich (Cat no.
C1832), and SRL was obtained from Merck Biosciences (Cat
no. 342500). Conﬂuent HMCs were treated with CsA, SRL,
or CsA/SRL cotreatment. Cells used in the inhibitor studies
were pretreated for 1 hour with UO126, prior to incubation
with each drug treatment.
2.2. Cell Morphology and Viability. HMC morphology was
analysed using phase contrast microscopy. Mesangial cell
viability was assessed using the resazurin conversion (Sigma-
Aldrich, 7017) cell viability assay. This assay was conducted
according to the manufacturer’s protocol. The viability of
the cells was expressed as a percentage of the absorbance
recorded for control cells.
2.3. Quantitative Polymerase Chain Reaction (PCR). Total
RNA was isolated using the trizol method from HMCs,
according to the manufacturer’s protocol (Sigma-Aldrich,
T9424). 1μg of total RNA was used to synthesis cDNA.
A Real-Time PCR TaqMan assay was used to quantify the
relative expression levels of genes of interest and has been
described previously [13]. Brieﬂy, cDNA was ampliﬁed on
the ABI 7900HT Sequence Detection System at default
thermal cycling conditions: 2min at 50◦C, 10min at 95◦C
for enzyme activation, and then 40 cycles of 15sec at
95◦Cf o rd e n a t u r a t i o na n d1 m i na t6 0 ◦C for annealing
and extension. Results were analysed using the delta Ct
method of analysis. Applied Biosystems commercial assays
were used for all genes of interest, TGF-β (Hs99999918 m1),
CTGF (Hs00170014 m1), and MMP-9 (Hs00234579 m1).
The ribosomal 18S gene was used as an endogenous control
for normalisation of the target genes. A negative control
containing all reaction components except for Superscript
for each set of samples was used.
2.4. TGF-β ELISA. AT G F - β1 ELISA was used to determine
the eﬀect CsA had on secreted TGF-β1 protein levels in
the media of HMCs. This was done according to the
manufacturing company’s (Cat no. DB100B, R&D systems)
protocol. The speciﬁcity and sensitivity of the assay was
assessedusing5ngofTGF-β1asapositive controlandsterile
water as a negative control.
2.5. TGF-β Smad Responsive Reporter Gene Assay. Transfec-
tion reagent-DNA complex was prepared by adding serum-
free medium to a sterile eppendorf tube. FuGene (Roche)
reagent was added directly to the tube and then 1μgo f
TGF-β Smad responsive (CAGA) luciferase reporter DNA
plasmid (a gift from Dr. Roel Goldschmeding) and 1μg
of control plasmid (renilla) (Promega). For multiple-well
addition, components were scaled up proportionally. Cells
were transfected overnight at 37◦C. Following transfection,
cells were treated with each immunosuppressive agent for
the required time period. Cells were lysed using passive lysis
buﬀer (Promega) and put into fresh tubes. The luminometer
was programmed to perform a 2-second premeasurement
delay followed by a 10-second measurement. Equal volumes
of cell lysate and Luciferase reagent were added together and
the luminescence reading recorded. Stop and glo reagent
was added to halt the reaction and another reading per-
formed. This process was repeated for all samples. Control
lysates were made from untransfected cells to determine
background luminescence levels and a positive control of
cells treated with 5ng TGF-β was used.
2.6. Western Blot Assay. Total protein was isolated from
HMCs using the RIPA buﬀer method (Sigma-Alridch,
R0278) according to the manufacturer’s protocol. The SDS-
PAGE procedure used was that of Laemmli [19]. Expres-
sion levels of renal proteins following CsA treatment was
determined by Western blot and has been described previ-
ously [15, 20, 21]. Proteins of interest were detected using
the following antibodies according to the manufacturer’s
protocol (rabbit anti-ERK 1/2, Cell Signalling Technology,
9211S and 9211). Time-matched controls were used in the
phosphorylation studies.
2.7. Statistical Analysis. Statistical analyses were performed
using GraphPad Prism 4.0. Data was analysed by one-way
analysis of variance (ANOVA), and multiple comparisons
between control and treatment groups were made using the
Bonferroni posttest. A student t-test was used for assessing
statistical diﬀerences between two groups. A probability of
0.05 or less was deemed statistically signiﬁcant. Results were
expressed as the mean ± SEM. The following scheme wasJournal of Transplantation 3
used throughout the work; ∗P<0.05, ∗∗P<0.01, ∗∗∗P<
0.001.
3. Results
3.1. CsA/SRL Caused Synergistic Nephrotoxicity in HMCs.
Microscopic examination highlighted that treatment with
CsA or SRL alone for 24 hours had no signiﬁcant eﬀect
on HMC morphology (Figure 1(a)). However, 24-hour
treatment with CsA/SRL combination did cause alterations
inHMCmorphology(Figure 1(a)).Anelongationofnormal
HMC shape accompanied with gaps in the cell monolayer
and cell death (indicated by round ﬂoating cells) was
observed. Treatment for 24 hour with CsA or SRL alone
had no signiﬁcant eﬀect on HMC viability. Treatment with
CsA/SRL drastically reduced HMC viability (100 versus 54±
3.9, P<0.05). The concentrations of CsA and SRL used in
this study were chosen following dose response studies, and
it approximates to concentrations used in vivo and reﬂect
concentrations in the kidney.
Treatment with CsA for 24 hours caused a signif-
icant increase in TGF-β1 secretion (843.1 ± 7.1v e r s u s
1089.5 ± 26.1pg/mL;P<0.05) as demonstrated by ELISA
(Figure 1(b)). SRL alone did not cause any signiﬁcant
alterations in TGF-β1 secretion following 24-hour adminis-
tration. However, cotreatment of CsA/SRL caused the most
signiﬁcant rise in TGF-β1 secretion (843.1 ± 7.1v e r s u s
1247.4 ± 10.4pg/mL; P<0.01). The increase in TGF-β1
secretion observed with CsA/SRL was signiﬁcantly greater
than the increase observed with CsA alone (1089.5 ± 26.1
versus 1247.4 ±10.4pg/mL;P<0.05).
To further examine the role of TGF-β, we decided to
investigate theeﬀectsofCsA, SRL,and CsA/SRL cotreatment
on a Smad-responsive luciferase construct. CsA treatment
caused a signiﬁcant increase in Smad activation (100 versus
156.9±1.7luciferaseunits;P<0.05).SRLadministrationdid
not signiﬁcantly alter Smad activation (100 versus 123.5 ±
4.3 luciferase units). Treatment with CsA/SRL cotreatment
c a u s e dt h eg r e a t e s ti n c r e a s ei nS m a da c t i v a t i o n( 1 0 0v e r s u s
210.1 ± 15.9 luciferase units; P<0.01). The increase in
Smad activation in the presence of CsA/SRL cotreatment was
signiﬁcantly greater than with CsA alone (156.9 ± 1.7v e r s u s
210.1 ±15.9 luciferase units; P<0.01) (Figure 1(c)).
3.2. CsA/SRL Cotreatment Increased CTGF and Decreased
MMP-9GeneExpression. TheobservationofincreasedSmad
signalling prompted an investigation into a downstream
mediator of TGF-β, connective tissue growth factor (CTGF).
Treatment for 24 hours with CsA showed a trend towards an
increase in CTGF gene expression, which was not statistically
signiﬁcant. Treatment with SRL alone caused no signiﬁcant
increase in CTGF gene expression. However, treatment with
CsA/SRL cotreatment caused a signiﬁcant increase in CTGF
gene expression (1 versus 2.0 ±0.02; P<0.01) (Figure 2(a)).
CsA treatment for 24 hours caused a signiﬁcant decrease
in matrix metalloproteinase 9 (MMP-9) gene expression (1.0
versus 0.18 ± 0.15; P<0.05). SRL also caused a signiﬁcant
reduction in MMP-9 gene expression. CsA/SRL cotreatment
also caused a signiﬁcant decrease in MMP-9 gene expression
(1 versus 0.37 ±0.2; P<0.05, Figure 2(b)).
3.3. CsA, SRL, and CsA/SRL Increased ERK 1/2 Activity in
HMCs. In order to determine the mechanism of CsA/SRL
co-treatment-induced alterations, we investigated the eﬀects
of CsA, SRL, and CsA/SRL on ERK 1/2 activation. CsA
signiﬁcantly increased ERK 1/2 phosphorylation after 15,
30, and 60 minutes administration (Figure 3(a)). SRL also
signiﬁcantly increased ERK 1/2 phosphorylation after 15 and
30 and 60 minutes treatment (Figure 3(b)). CsA/SRL co-
treatment caused a synergistic increase in ERK 1/2 phospho-
rylationat15,30,and60minutes.However,thecombination
of CsA/SRL co-treatment also signiﬁcantly increased ERK
1/2 phosphorylation at 24 and 48 hours, unlike the CsA and
SRL individual treatments (Figure 3(c)).
3.4. Inhibition of ERK 1/2 Provided Partial Protection against
CsA/SRL Cytotoxicity. The addition of UO126 prevented the
CsA, SRL, and CsA/SRL co-treatment-induced stimulation
of ERK 1/2 (Figure 4). Total levels of ERK 1/2 protein were
unaltered following CsA, SRL, or CsA/SRL combination in
the presence or absence of UO126 treatment. It was upon
the notable activation of ERK 1/2 phosphorylation that
the eﬀect of 24-hour CsA/SRL treatment in the presence
of the ERK 1/2 inhibitor UO126 was examined (Figure 5).
ERK 1/2 inhibition appeared to partially ameliorate the
CsA/SRL co-treatment-induced morphological alterations
in HMCs. However, there were still some gaps visible in
the monolayer. The CsA/SRL-induced reduction in HMC
viability was prevented to some extent by ERK inhibition
(54 ± 3.9v e r s u s8 8± 3.5, P<0.001). The addition of the
ERK inhibitor alone caused no eﬀect on HMC viability or
morphology.
Inhibition of ERK 1/2 phosphorylation prevented the
CsA alone and CsA/SRL co-treatment-induced increases in
TGF-βsecretion(Figure 4).(CsA+UO126, 518±23.5v e r s u s
1089 ± 26.1, CsA, P<0.001). (CsA/SRL + UO126, 424 ±
54.2 versus 1247 ± 10.4, CsA/SRL, P<0.001). ERK inhibi-
tionalsosigniﬁcantlyreducedcontrolandSRLlevelsofTGF-
β1s e c r e t i o n .
ERK inhibition also dramatically reduced the CsA/SRL-
induced increase in CTGF gene expression to below control
levels (CsA/SRL, 1.7 ± 0.2v e r s u s0 .6 ± 0.14, CsA/SRL +
UO126). ERK inhibition also signiﬁcantly reduced control
CTGF gene expression (Figure 4). ERK inhibition also
prevented the previously observed CsA/SRL co-treatment-
induced decrease in MMP-9 gene expression (0.37 ± 0.25
versus 1.6 ± 0.2; P<0.001) (Figure 4). ERK inhibition also
restored the CsA- and SRL-induced decreases in MMP-9 and
restored MMP-9 values to control levels. UO126 alone did
not signiﬁcantly alter MMP-9 gene expression.
4. Discussion
The results presented in this body of work demonstrated that
the combination treatment of CsA and SRL did not result
in an attenuation of the CNI-associated changes in HMCs
but in fact resulted in synergistic nephrotoxic-like eﬀects. It4 Journal of Transplantation
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Figure 1: CsA/SRL caused synergistic nephrotoxicity by increasing TGF-β and smad signalling in HMCs. HMCs were grown to conﬂuency
andtreatedwithvehicle,4.2μMCsA,1μMSRLorCsA/SRL,4.2μMCsA+1μMSRLfor24hours.(a)Phasecontrastmicrographsweretaken
usingaCCDcameramountedonaNikonmicroscope.Magniﬁcation200X.Cellviabilitywasmeasuredusingtheresazurinconversionassay.
(b) 24-hour TGF-β1 secretion was detected using a TGF-β1 ELISA. (c) Smad activation was measured using a Smad responsive luciferase
construct. Smad responsive luciferase values were normalised to a control renilla luciferase construct. Each column represents the mean ±
SEM of a minimum of 3 independent experiments performed in duplicate. Data was analysed by ANOVA and comparisons between control
and multiple treatment groups were made using the Dunnet posttest. ∗Indicates statistical diﬀerence compared to control. ∗P<0.05,
∗∗P<0.01.
appeared that the primary causative factor for the CsA/SRL-
induced mesangial cell dysfunction was a signiﬁcant dual
increase in TGF-β and CTGF expression. We also observed
enhanced activation of the ERK 1/2 MAPK pathway, the
TGF-β signalling pathway, and alteration of ECM regulators.
Altered HMC morphology and viability gave the ﬁrst
indication that CsA and SRL combination treatment was
exerting a detrimental eﬀect when administered to HMCs
in the present study. These initial ﬁndings of enhanced
toxicity were surprising as it had been previously reported
that SRL had a protective role and could reduce the toxicity
observed with CNI administration [22, 23]. However, more
recently, experimental evidence has emerged suggesting that
a combination of CsA and SRL might not be protective. In a
rat model, kidney function and morphology were assessed
following short-term combination therapy with CsA, and
SRL[9].Stripedﬁbrosisandglomerularﬁltrationrate(GFR)
were signiﬁcantly worse in rats receiving CsA and SRL
combination according to the study by Nielsen et al. [9].
WeobservedthatthesecretionofTGF-β wassigniﬁcantly
increased following immunosuppressive drug treatment in
the present model. TGF-β is a major factor involved in CsA-
induced renal ﬁbrosis and renal disease [24]. TGF-β has
been shown to be upregulated in a number of in vitro and
in vivo experimental models following CsA treatment and
in patients undergoing CsA therapy [14, 15, 25]. Increased
TGF-β m a yh a v ec o n t r i b u t e dt ot h ea d v e r s ee ﬀects observed
in the present study. The lack of an increase in TGF-β asJournal of Transplantation 5
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Figure 2: CsA/SRL cotreatment increased CTGF and decreased MMP-9 gene expression in HMCs. HMCs were grown to conﬂuency and
treated with vehicle, 4.2μMC s A ,1μM SRL or CsA/SRL, 4.2μMC s A+1μM SRL for 24 hours. CTGF and MMP-9 expression was detected
by quantitative PCR. (a) 24-hour CTGF gene expression and (b) MMP-9 gene expression. Each column represents the mean ± SEM of
a minimum of 3 independent experiments performed in duplicate. Data was analysed by ANOVA and comparisons between control and
multipletreatmentgroupsweremadeusingtheDunnetposttest. ∗Indicatesstatisticaldiﬀerencecomparedtocontrol. ∗P<0.05, ∗∗P<0.01.
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Figure 3: CsA/SRL cotreatment caused a biphasic increase in ERK 1/2 activity in HMCs. HMCs were grown to conﬂuency and treated with
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Figure 4: The MEK inhibitor, U0126, blocked CsA- and SRL-
induced ERK 1/2 activity in HMCs. HMCs were grown to conﬂu-
ency and treated with vehicle, 4.2μMC s A ,1μM SRL, or CsA/SRL
4.2μMCsA+1μMSRLinthepresenceorabsenceof10μMUO126
for up to 48 hours. Phosphorylated ERK 1/2 MAPK or whole-cell
ERK 1/2 MAPK was probed by Western blotting. Representative
blots from one of three independent experiments are shown.
observed with SRL alone in the current study may help to
explain the reduced nephrotoxic side eﬀects associated with
SRL [4].
It is accepted now that altered pharmacokinetics have a
role in contributing to the observed toxicity with a combi-
nation of SRL and CsA [26]. An in vitro study in human
renal epithelial cells demonstrated that SRL prolonged the
intracellular accumulation of CsA when given in combina-
tion. The authors showed that SRL inhibited P-glycoprotein-
mediated eﬄux contributing to CsA nephrotoxicity [27].
However, the reasons for the augmented nephrotoxicity
resulting from a combination of SRL and CsA still remain
to be fully deﬁned, with some studies attributing the eﬀect to
pharmacokinetics and others to hyperglycaemia [10, 26, 27].
Another known contributor to CsA nephrotoxicity is TGF-β.
In the present HMC model, SRL had a synergistic
eﬀect on TGF-β secretion when coadministered with CsA.
However, similar increases in TGF-β were also reported in
a study on CsA and SRL combination therapy by Shihab et
al. [11]. In that study, rats were given doses of CsA alone,
SRL alone, or a combination of CsA and SRL. The authors
observed a worsening in renal function in the group that
were given CsA and SRL in combination compared to CsA
and SRL alone. The CsA/SRL group also exhibited tubular
injury, interstitial ﬁbrosis, and arteriolopathy as indicated by
histological analysis. Elevated TGF-β protein levels were also
observed in the CsA and SRL co-treatment groups, and the
levels were signiﬁcantly higher than with CsA or SRL alone
[11]. To our knowledge, however, this is the ﬁrst time that
this eﬀect has been observed in HMCs.
One downstream mediator of TGF-β is CTGF. CTGF was
upregulated in the present HMC model following CsA/SRL
co-treatment. CTGF has been found to be upregulated in
many inﬂammatory glomerular diseases and in patient biop-
sies with numerous diﬀerent conditions including glomeru-
lonephritis and focal segmental glomerulosclerosis [28]. It
appeared that a novel dual elevation of TGF-β and CTGF
in the HMCs following CsA/SRL co-treatment contributed
to the enhanced CsA/SRL-induced mesangial cell alterations.
This dual elevation of TGF-β and CTGF was not observed
following treatment with CsA or SRL alone.
In the current study, CsA/SRL may also have altered
ECM turnover by decreasing MMP-9 levels. The observed
reduction in MMP-9 in the present mesangial cell model
may have facilitated ECM accumulation by preventing ECM
degradation. It is known that ECM regulators are extremely
context speciﬁc and chronologically variable [29]. In models
of chronic kidney disease, decreased MMP-9 has been shown
to aid disease progression. In a rat ischemia-reperfusion
model, Caron et al. observed that MMP-9 was signiﬁcantly
upregulated and may have contributed to glomerular injury
[30]. In another model, transgenic mice overexpressing
renin developed hypertension-induced renal dysfunction.
Isolated glomeruli from these mice exhibited elevated TGF-β
accompanied with decreased MMP-9 gene expression [31].
These alterations in HMCs following CsA/SRL treatment
are at least in part due to enhanced signalling through the
ERK 1/2 pathway. Previous studies in our laboratory have
indicated that the MAPK pathways are also activated in
response to CsA in Madin Darby canine kidney (MDCK)
epithelial cells [32, 33]. A biphasic activation of ERK 1/2
following CsA/SRL co-treatment was observed in the HMCs
and may be the mechanism by which the synergistic nephro-
toxic eﬀect is exerted by the CsA/SRL co-treatment. This is
furthersupportedbythefactthatERK1/2inhibitionresulted
in signiﬁcant attenuation of this CsA/SRL-induced HMC
dysfunction.Consideringthewell-characterisedrolesofERK
1/2 signalling in cell survival and proliferation, our ﬁnding
that enhanced ERK 1/2 signalling is central to CsA/SRL cyto-
toxicity is interesting. These observations are in keeping with
other studies in HMCs. Ishikawa and Kitamura observed
that incubation of cultured HMCs with hydrogen peroxide
induced apoptosis [34]. This apoptosis was accompanied by
activation of the ERK 1/2 MAPK pathway. Pharmacological
inhibition of ERK 1/2 attenuated the hydrogen peroxide-
induced mesangial cell apoptosis [34]. Similarly, in cisplatin-
induced cytotoxicity, ERK 1/2 has been shown to play a
central role [35]. Several mechanisms of ERK 1/2-mediated
cytotoxicity have been proposed including ERK-dependent
activation of caspases [36] and induction of autophagy [37].
Importantly from the perspective of this study, in examples
of ERK-mediated cytotoxicity, ERK activation is unusually
prolonged (up to 72 hours) [38]. Therefore, the prolonged
ERK activation observed in this study, in the presence of
CsA/SRL co-treatment, may be a key mechanistic diﬀerence
compared to the two immunosuppressants in isolation.
Blockade of the ERK 1/2 pathway also caused signiﬁcant
attenuation of TGF-β secretion. This suggests that the ERK
1/2 pathway may play a major role in TGF-β signalling.
ERK 1/2 also appeared to play a role in CTGF expression
in this mesangial cell model as CTGF gene expression was
attenuated by ERK inhibition. These observations have been
observed in other models of CsA nephrotoxicity [39, 40].
Our proposed mechanism for the enhanced CsA/SRL
nephrotoxicity is that CsA/SRL strongly activates ERK 1/2,
which promotes TGF-β cellular secretion. The excess TGF-β
thenpromotesincreasedCTGFviatheSmadpathway.TGF-βJournal of Transplantation 7
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Figure 5: ERK 1/2 inhibition attenuated the CsA/SRL-induced alterations in HMCs. HMCs were grown to conﬂuency and pretreated
with UO126 10μM for 1-hour prior to treatment with vehicle control, 4.2μMC s A ,1μM SRL, or CsA/SRL 4.2μM+1μM, for 24 hours.
phase contrast micrographs were taken using a CCD camera mounted on a Nikon microscope. (a) Magniﬁcation 200X. HMC viability
was measured using the Resazurin Conversion Assay. (b) TGF-β1 secretion was detected using a TGF-β1 ELISA. (c) 24-hour CTGF gene
expression and 24-hour MMP-9 gene expression. Gene expression was detected by quantitative PCR. Each column represents the mean ±
SEM of a minimum of 3 independent experiments performed in duplicate. Data was analysed by ANOVA and comparisons between control
and multiple treatment groups were Mmade using the Dunnet Posttest.∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
may also promote decreased ECM degradation via decreased
MMP9, which contributes to the observed mesangial cell
dysfunction. These ﬁndings are important in determining
future immunosuppression strategies for SRL therapy in
clinical organ transplantation. Currently, there are two
main strategies: de novo use of SRL in combination with
reduced amounts of CsA or complete conversion from a
CNI-based protocol to SRL in cases where well-recognized
adverse eﬀects of CNIs (such as impaired renal function)
are prevalent [33]. However, there is much debate on this
issue and longer-term studies in larger cohorts of patients
are required to determine whether replacement of CsA with
SRL provides any signiﬁcant improvement in patient and
graft survival [33]. The results shown in this study would8 Journal of Transplantation
suggest that long-term use of SRL in patients will have
serious nephrotoxic eﬀects.
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